{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:58Z","timestamp":1791999478970,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012206","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000}}],"reference-count":138,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012206.pub2","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T07:40:12Z","timestamp":1689579612000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Non-surgical therapies for Peyronie's disease"],"prefix":"10.1002","volume":"2023","author":[{"given":"Joel E","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Urology; University of California San Diego; San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onuralp","family":"Ergun","sequence":"additional","affiliation":[{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"},{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu Chang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Urology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Risk","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hung","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Urology; Yonsei University Wonju College of Medicine; Wonju Korea, South"},{"name":"Center of Evidence-Based Medicine, Institute of Convergence Science; Yonsei University; Seoul Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E","family":"Edwards","sequence":"additional","affiliation":[{"name":"University of Florida Health Science Center Libraries; University of Florida; Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yooni","family":"Blair","sequence":"additional","affiliation":[{"name":"Department of Urology; University of Michigan; Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"},{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"issue":"4S","key":"10.1002\/14651858.CD012206.pub2-BIB0001|cit1","first-page":"e957","article-title":"The efficacy of botulinum toxin type A in treating Peyronie's disease","volume":"201","author":"Antar","year":"2019","journal-title":"Journal of Urology"},{"issue":"9","key":"10.1002\/14651858.CD012206.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","article-title":"Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial","volume":"106","author":"Chitale","year":"2010","journal-title":"British Journal of Urology International"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0003|cit3","first-page":"165","article-title":"Betamethasone versus placebo in Peyronie's disease","volume":"70","author":"Cipollone","year":"1998","journal-title":"Archivio Italiano Di Urologia, Andrologia"},{"issue":"6","key":"10.1002\/14651858.CD012206.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"Journal of Urology"},{"issue":"11","key":"10.1002\/14651858.CD012206.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1111\/jsm.12312","article-title":"Baseline characteristics from an ongoing phase 3 study of collagenase Clostridium histolyticum in patients with Peyronie's disease","volume":"10","author":"Gelbard","year":"2013","journal-title":"Journal of Sexual Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.urology.2015.04.047","article-title":"Self-report and clinical response to Peyronie's disease treatment: Peyronie's disease questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies","volume":"86","author":"Hellstrom","year":"2015","journal-title":"Urology"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","article-title":"Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies","volume":"116","author":"Lipshultz","year":"2015","journal-title":"British Journal of Urology International"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1016\/S1569-9056(15)60136-1","article-title":"Peyronie's disease symptom bother reduction is related to penile curvature improvement in response to treatment with collagenase Clostridium histolyticum: results from two large double-blind, randomized, placebo-controlled phase 3 studies","volume":"14","author":"Lipshultz","year":"2015","journal-title":"European Urology, Supplements"},{"issue":"11","key":"10.1002\/14651858.CD012206.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/jsm.12275","article-title":"Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study","volume":"10","author":"Hatzichristodoulou","year":"2013","journal-title":"Journal of Sexual Medicine"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Sokolakis I Lahme S Hatzzichristodoulou G Extracorporeal shockwave therapy (ESWT) for the treatment of Peyronie's disease: long-term results from a prospective randomized sham-controlled trial Journal of Sexual Medicine 2020","DOI":"10.1016\/j.jsxm.2020.04.052"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1743-6109.2005.00110.x","article-title":"The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease","volume":"2","author":"Kendirci","year":"2005","journal-title":"Journal of Sexual Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bju.14602","article-title":"Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study","volume":"123","author":"Moncada","year":"2019","journal-title":"British Journal of Urology International"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/RRU.S325929","article-title":"A randomized, single-blinded clinical trial evaluating the effect of extracorporeal shockwave treatment (ESWT) as add-on therapy to vacuum erectile device on Peyronie\u2019s disease","volume":"13","author":"Mortensen","year":"2021","journal-title":"Research and Reports in Urology"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","article-title":"A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease","volume":"56","author":"Palmieri","year":"2009","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"issue":"11","key":"10.1002\/14651858.CD012206.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1111\/j.1743-6109.2010.01924.x","article-title":"Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial","volume":"7","author":"Soh","year":"2010","journal-title":"Journal of Sexual Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner","year":"2005","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a novel penile traction device in men with Peyronie's disease: a randomized, single-blind, controlled trial","volume":"202","author":"Ziegelmann","year":"2019","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0021|cit21","first-page":"23","article-title":"Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline","volume":"6(7 Spec No)","author":"Alizadeh","year":"2014","journal-title":"Global Journal of Health Science"},{"issue":"S2","key":"10.1002\/14651858.CD012206.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S2666-1683(20)35331-3","article-title":"Impact of extracorporeal shock wave therapy for erectile dysfunction and Peyronie's disease on hormonal and reproductive testicular function: results from a randomized controlled trial","volume":"20","author":"Amicuzi","year":"2020","journal-title":"European Urology Open Science"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report","volume":"88","author":"Biagiotti","year":"2001","journal-title":"British Journal of Urology International"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0024|cit24","unstructured":"Cai T Tiscione D Favilla V Puglisi M Palumbo F Zucchi A Oral administration and intralesional injection of hyaluronic acid versus intralesional injection alone in Peyronie's disease: results from a phase III study World Journal of Men's Health 1 7 10.5534\/wjmh.200048"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0025|cit25","first-page":"413","article-title":"Peyronie's disease: treatment with interferon and laser","volume":"61","author":"Candebat Montero","year":"2008","journal-title":"Archivos Espa\u00f1oles de Urolog\u00eda"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0026|cit26","first-page":"191","article-title":"Meaningful change in Peyronie's disease following treatment with collagenase Clostridium histolyticum: results from two large double-blind, randomized, placebo-controlled phase 3 studies","volume":"12","author":"Carson","year":"2015","journal-title":"Journal of Sexual Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012206.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1464-410X.2002.02738.x","article-title":"Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease","volume":"89","author":"Cavallini","year":"2002","journal-title":"British Journal of Urology International"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.urology.2007.01.080","article-title":"Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease","volume":"69","author":"Cavallini","year":"2007","journal-title":"Urology"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.SMJ.0000056658.60032.D3","article-title":"Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease","volume":"97","author":"Dang","year":"2004","journal-title":"Southern Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S1569-9056(15)60134-8","article-title":"The association of tadalafil and intralesional verapamil injection is an effective therapy in the medical treatment of Peyronie's disease","volume":"14","author":"Dell'Atti","year":"2015","journal-title":"European Urology, Supplements"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie's disease","volume":"7","author":"Dell'Atti","year":"2015","journal-title":"Urology Annals"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","article-title":"A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease","volume":"171","author":"Di Stasi","year":"2004","journal-title":"Journal of Urology"},{"issue":"8","key":"10.1002\/14651858.CD012206.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/and.12178","article-title":"Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study","volume":"46","author":"Favilla","year":"2014","journal-title":"Andrologia"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0034|cit34","first-page":"25","article-title":"Laser and ultrasonic therapy in simultaneous emission for the treatment of plastic penile induration","volume":"47","author":"Felipetto","year":"1995","journal-title":"Minerva Urologica e Nefrologica"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","article-title":"Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease-a placebo-controlled pilot study","volume":"4","author":"Easterling","year":"2007","journal-title":"Journal of Sexual Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","article-title":"Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"Journal of Urology"},{"issue":"10","key":"10.1002\/14651858.CD012206.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s11255-015-1074-1","article-title":"Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease","volume":"47","author":"Gennaro","year":"2015","journal-title":"International Urology and Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1743-6109.2007.00581.x","article-title":"The use of collagenase in the treatment of Peyronie's disease M.K. Gelbard, A. Lindner, and J.J. Kaufman","volume":"4","author":"Glina","year":"2007","journal-title":"Journal of Sexual Medicine"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/JU.0000000000000743","article-title":"Long-term safety and curvature deformity characterization in patients previously treated with collagenase Clostridium histolyticum for Peyronie's disease","volume":"203","author":"Goldstein","year":"2020","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","article-title":"Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial","volume":"177","author":"Greenfield","year":"2007","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0041|cit41","first-page":"291","article-title":"Evaluation of intralesional injection of verapamil in treatment of Peyronie's disease","volume":"60","author":"Heidari","year":"2010","journal-title":"Journal of the Pakistan Medical Association"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study","volume":"67","author":"Inal","year":"2006","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jsxm.2020.10.003","article-title":"Outcomes of restoreX penile traction therapy in men with Peyronie\u2019s disease: results from open label and follow-up phases","volume":"17","author":"Joseph","year":"2020","journal-title":"Journal of Sexual Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","article-title":"Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"Journal of Sexual Medicine"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0045|cit45","first-page":"128","article-title":"Peyronie's disease symptom bother reduction is related to penile curvature improvement in response to treatment with collagenase clostridium histolyticum: results from two large double-blind, randomized, placebo-controlled phase 3 studies","volume":"12","author":"Lipshultz","year":"2015","journal-title":"Journal of Sexual Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.2047-2927.2012.00018.x","article-title":"Comparison of transdermal electromotive administration of verapamil and dexamethasoneversus intra-lesional injection for Peyronie's disease","volume":"1","author":"Mehrsai","year":"2013","journal-title":"Andrology"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000020013","article-title":"Our experience on the association of a new physical and medical therapy in patients sufferingfrom induratio penis plastica","volume":"36","author":"Mirone","year":"1999","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0048|cit48","first-page":"384","article-title":"Ultrasound-guided ESWT in Peyronie's disease plaques","volume":"72","author":"Mirone","year":"2000","journal-title":"Archivio Italiano Di Urologia, Andrologia"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/j.1939-4640.2000.tb03279.x","article-title":"Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results","volume":"21","author":"Montorsi","year":"2000","journal-title":"Journal of Andrology"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","article-title":"Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction","volume":"183","author":"Ozturk","year":"2014","journal-title":"Irish Journal of Medical Science"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","article-title":"Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial","volume":"35","author":"Palmieri","year":"2012","journal-title":"International Journal of Andrology"},{"issue":"6","key":"10.1002\/14651858.CD012206.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1871528112666131205112432","article-title":"Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and localdiclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study","volume":"12","author":"Paulis","year":"2013","journal-title":"Inflammation & Allergy Drug Targets"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000467396","article-title":"Does transfer capacitive resistive energy has a therapeutic effect on peyronie's disease? Randomized, single-blind, sham-controlled study on 96 patients: fast pain relief","volume":"99","author":"Pavone","year":"2017","journal-title":"Urologia Internationalis"},{"issue":"6","key":"10.1002\/14651858.CD012206.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","article-title":"Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease","volume":"91","author":"Prieto Castro","year":"2003","journal-title":"British Journal of Urology International"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2005.04.011","article-title":"Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study","volume":"48","author":"Riedl","year":"2005","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","article-title":"Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study","volume":"16","author":"Safarinejad","year":"2004","journal-title":"International Journal of Impotence Research"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD012206.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad","year":"2007","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD012206.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/j.1743-6109.2009.01235.x","article-title":"Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: a prospective, randomized, double-blind placebo-controlled study","volume":"6","author":"Safarinejad","year":"2009","journal-title":"Journal of Sexual Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0059|cit59","first-page":"298","article-title":"Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study","volume":"22","author":"Safarinejad","year":"2010","journal-title":"Journal of Impotence Research"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","article-title":"A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease","volume":"106","author":"Safarinejad","year":"2010","journal-title":"British Journal of Urology International"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0061|cit61","first-page":"1562","article-title":"Re: Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study","volume":"195","author":"Seftel","year":"2016","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0062|cit62","first-page":"189","article-title":"How to improve extracorporeal shock wave therapy in the management of patients with Peyronie's disease? Results from a randomized trial comparing plaque injection either with a saline solution or with a hydrocortisone solution","volume":"12","author":"Sempels","year":"2015","journal-title":"Journal of Sexual Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"International Urology and Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD012206.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","article-title":"Tamoxifen versus placebo in the treatment of Peyronie's disease","volume":"162","author":"Teloken","year":"1999","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0065|cit65","first-page":"7","article-title":"Intraplaque injection of tiocolchicine and verapamil in Peyronie's disease patients: a prospective randomized single-blind comparative study","volume":"12","author":"Rezende","year":"2015","journal-title":"Journal of Sexual Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1590\/S1677-5538.IBJU.2015.0598","article-title":"A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's disease: a pilot study","volume":"42","author":"Rezende","year":"2016","journal-title":"International Brazilian Journal Of Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0067|cit67","first-page":"1","article-title":"Correction: \u201cTopical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H100: a randomized, prospective, placebo-controlled pilot study\u201d","volume":"Published onlin","author":"Twidwell","year":"2020","journal-title":"Your Sexual Medicine Journal"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ijir.2015.22","article-title":"Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study","volume":"28","author":"Twidwell","year":"2016","journal-title":"International Journal of Impotence Research"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.urology.2015.04.049","article-title":"Editorial comment: Self-report and clinical response to Peyronie's disease treatment: Peyronie's Disease Questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies","volume":"86","author":"Watkin","year":"2015","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0070|cit70","unstructured":"Assessment of treatment efficacy of Nd-YAG laser beside intra lesion verapamil injection in Peyronie\u2019s disease patients referring to Shohada-e-Tajrish hospital: a randomized clinical trial https:\/\/www.irct.ir\/trial\/8585"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0071|cit71","unstructured":"Low-intensity extracorporeal shockwave therapy and vacuum erectile device as a treatment for Peyronie's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03530540"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0072|cit72","unstructured":"Agency for Healthcare Research and Quality Methods Guide for Effectiveness and Comparative Effectiveness Reviews AHRQ Publication 2015 No. 10(14)-EHC063-EF"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.sxmr.2020.12.004","article-title":"Platelet-rich plasma injections for erectile dysfunction and peyronie's disease: a systematic review of evidence","volume":"10","author":"Alkandari","year":"2022","journal-title":"Sexual Medicine Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ijir.3901518","article-title":"The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction","volume":"19","author":"Arafa","year":"2007","journal-title":"International Journal of Impotence Research"},{"issue":"10","key":"10.1002\/14651858.CD012206.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jsxm.2021.06.012","article-title":"Extracorporeal shockwave therapy in Peyronie's disease: systematic review and meta-analysis","volume":"18","author":"Bakr","year":"2021","journal-title":"Journal of Sexual Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.sxmr.2017.07.011","article-title":"Intralesional injection of collagenase clostridium histolyticum may increase the risk of late-onset penile fracture","volume":"6","author":"Beilan","year":"2018","journal-title":"Sexual Medicine Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.5489\/cuaj.5255","article-title":"2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature","volume":"12","author":"Bella","year":"2018","journal-title":"Canadian Urological Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"310","DOI":"10.21037\/tau.2016.03.15","article-title":"Injectable therapy for Peyronie\u2019s disease","volume":"5","author":"Chong","year":"2016","journal-title":"Translational Andrology and Urology"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41443-020-0244-6","article-title":"Funding Peyronie's disease: funding sources for primary research literature","volume":"33","author":"Christiansen","year":"2021","journal-title":"International Journal of Impotence Research"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0080|cit80","unstructured":"Chu KY Molina ML Ledesma B Zucker I Saltzman RG Masterson TA A phase 2 randomized, placebo-controlled crossover trial to evaluate safety and efficacy of platelet-rich plasma injections for Peyronie's disease: clinical trial update European Urology Focus 10.1016\/j.euf.2022.08.017"},{"issue":"6","key":"10.1002\/14651858.CD012206.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on Peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"Journal of Sexual Medicine"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bju.15057","article-title":"A clinical pathway for the management of Peyronie's disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association","volume":"126 Suppl 1","author":"Chung","year":"2020","journal-title":"BJU International"},{"issue":"9","key":"10.1002\/14651858.CD012206.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14656566.2022.2043274","article-title":"Pharmacotherapy in Peyronie's disease: a state-of-the-art review on established contemporary and emerging drugs","volume":"23","author":"Chung","year":"2022","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2019.11.019","article-title":"The end of an era: withdrawal of Xiapex (Clostridium histolyticum collagenase) from the European market","volume":"77","author":"Cocci","year":"2020","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0085|cit85","unstructured":"Covidence Veritas Health Innovation"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jsxm.2016.10.015","article-title":"Moving from consensus- to evidence-based clinical practice guidelines for Peyronie's disease","volume":"14","author":"Dahm","year":"2017","journal-title":"Journal of Sexual Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0087|cit87","first-page":"102","article-title":"The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale","volume":"86","author":"DeLoach","year":"1998","journal-title":"Anesthesia and Analgesia"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","article-title":"A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States","volume":"2011","author":"DiBenedetti","year":"2011","journal-title":"Advances in Urology"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/andr.12927","article-title":"Medical, non-invasive, and minimally invasive treatment for Peyronie's disease: a systematic review","volume":"9","author":"El-Sakka","year":"2021","journal-title":"Andrology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0090|cit90","unstructured":"Endnote X7.4 Thomson Reuters"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/andr.12368","article-title":"Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study","volume":"5","author":"Favilla","year":"2017","journal-title":"Andrology"},{"issue":"8-9","key":"10.1002\/14651858.CD012206.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.purol.2020.11.004","article-title":"French Urological Association (AFU) guidelines for Peyronie's disease assessment and treatment","volume":"31","author":"Ferretti","year":"2021","journal-title":"Progr\u00e8s en Urologie"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"100387","DOI":"10.1016\/j.esxm.2021.100387","article-title":"The use of penile traction devices for Peyronie's disease: position statements from the European Society for Sexual Medicine","volume":"9","author":"Garcia-Gomez","year":"2021","journal-title":"Sexual Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/0973-1482.139263","article-title":"A comparative study on efficacy of different treatment modalities of oral submucous fibrosis evaluated by clinical staging in population of Southern Rajasthan","volume":"11","author":"Goel","year":"2015","journal-title":"Journal of Cancer Research and Therapeutics"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0096|cit96","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","article-title":"Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial","volume":"177","author":"Greenfield","year":"2007","journal-title":"Journal of Urology"},{"issue":"7651","key":"10.1002\/14651858.CD012206.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"issue":"12","key":"10.1002\/14651858.CD012206.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence \u2013 imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","article-title":"Bother and distress associated with Peyronie's disease: validation of the Peyronie's diseasequestionnaire","volume":"190","author":"Hellstrom","year":"2013","journal-title":"Journal of Urology"},{"issue":"11","key":"10.1002\/14651858.CD012206.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD012206.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0106|cit106","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0107|cit107","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study","volume":"67","author":"Inal","year":"2006","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1477-7525-11-109","article-title":"Patient-reported outcomes in meta-analyses \u2013 Part 1: assessing risk of bias and combining outcomes","volume":"11","author":"Johnston","year":"2013","journal-title":"Health and Quality of Life Outcomes"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/emj.18.3.205","article-title":"The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain","volume":"18","author":"Kelly","year":"2001","journal-title":"Emergency Medicine Journal"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3342\/ceo.2009.2.1.20","article-title":"Effect of botulinum toxin type A on a rat surgical wound model","volume":"2","author":"Lee","year":"2009","journal-title":"Clinical and Experimental Otorhinolaryngology"},{"issue":"7","key":"10.1002\/14651858.CD012206.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jsxm.2020.11.013","article-title":"Comparing and contrasting Peyronie's disease guidelines: points of consensus and deviation","volume":"18","author":"Manka","year":"2021","journal-title":"Journal of Sexual Medicine"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012206.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","article-title":"Expanding the paradigm for plaque development in Peyronie's disease","volume":"15","author":"Mulhall","year":"2003","journal-title":"International Journal of Impotence Research"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie's Disease: AUA Guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.12926","article-title":"Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia - integrated data from 1,499 study participants","volume":"115","author":"Nickel","year":"2015","journal-title":"British Journal of Urology International"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5534\/wjmh.2016.34.1.40","article-title":"The efficacy of medical treatment of Peyronie's disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, l-carnitine, and phosphodiesterase type 5 inhibitor","volume":"34","author":"Park","year":"2016","journal-title":"World Journal of Mens Health"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.sxmr.2022.08.001","article-title":"A consistent lack of consistency in defining the acute and chronic phases of Peyronie's disease: a review of the contemporary literature","volume":"10","author":"Piraino","year":"2022","journal-title":"Sexual Medicine Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.ijir.3900877","article-title":"Clinical presentations of Peyronie's disease","volume":"14","author":"Pryor","year":"2002","journal-title":"International Journal of Impotence Research"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0121|cit121","unstructured":"Pyrgidis N Yafi FA Sokolakis I Dimitriadis F Mykoniatis I Russo GI Assessment of conservative combination therapies for active and stable Peyronie's disease: a systematic review and meta-analysis European Urology Focus 10.1016\/j.euf.2021.12.003"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"175628721882367","DOI":"10.1177\/1756287218823671","article-title":"Non-invasive treatment in the management of Peyronie's disease","volume":"11","author":"Randhawa","year":"2019","journal-title":"Therapeutic Advances in Urology"},{"issue":"4","key":"10.1002\/14651858.CD012206.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0124|cit124","unstructured":"Retraction Watch Database http:\/\/retractiondatabase.org\/RetractionSearch.aspx?"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0125|cit125","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"6","key":"10.1002\/14651858.CD012206.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"issue":"6","key":"10.1002\/14651858.CD012206.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2018.07.005","article-title":"Clinical Efficacy of injection and mechanical therapy for Peyronie's disease: a systematic review of the literature","volume":"74","author":"Russo G","year":"2018","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD012206.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jsxm.2018.12.011","article-title":"Comparative effectiveness of intralesional therapy for Peyronie's disease in controlled clinical studies: a systematic review and network meta-analysis","volume":"16","author":"Russo","year":"2019","journal-title":"Journal of Sexual Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2021.06.007","article-title":"European Association of Urology Guidelines on Sexual and Reproductive Health\u20142021 Update: Male Sexual Dysfunction","volume":"80","author":"Salonia","year":"2021","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0130|cit130","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jrsm.1078","article-title":"Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions","volume":"4","author":"Schunemann","year":"2013","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0022-5347(17)40920-7","article-title":"Isolation and characterization of collagen in Peyronie's disease","volume":"141","author":"Somers","year":"1989","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD012206.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jsxm.2019.09.022","article-title":"Impact of the advent of collagenase Clostridium histolyticum on the surgical management of Peyronie's disease: a population-based analysis","volume":"17","author":"Sukumar","year":"2020","journal-title":"Journal of Sexual Medicine"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.urology.2018.06.049","article-title":"Multi-institutional prospective analysis of intralesional injection of collagenase clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie's disease","volume":"120","author":"Yafi F","year":"2018","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012206.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2017.04.045","article-title":"Self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase clostridium histolyticum injections for Peyronie disease","volume":"106","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD012206.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jsxm.2019.11.271","article-title":"Peyronie's disease intervention studies: an exploration of modern-era challenges in study design and evaluating treatment outcomes","volume":"17","author":"Ziegelmann","year":"2020","journal-title":"Journal of Sexual Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012206.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012206","article-title":"Non-surgical therapies for Peyronie's disease","author":"Pagliara","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:06:37Z","timestamp":1760313997000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012206.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":138,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012206.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}